DAR 901

Drug Profile

DAR 901

Alternative Names: Heat-killed Mycobacterium vaccae strain NCTC 11659; SRL 172

Latest Information Update: 08 Aug 2016

Price : $50

At a glance

  • Originator SR Pharma
  • Developer Aeras; Dartmouth College; Tokyo Medical and Dental University
  • Class Adjuvants; Antineoplastics; Antivirals; Tuberculosis vaccines
  • Mechanism of Action Immunomodulators; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Tuberculosis
  • Discontinued Asthma; Atopic dermatitis; Hepatitis B; Malignant melanoma; Mesothelioma; Non-small cell lung cancer; Prostate cancer; Renal cancer; Seasonal allergic rhinitis; Small cell lung cancer

Most Recent Events

  • 01 Jun 2016 Dartmouth-Hitchcock Medical Center completes phase I clinical trials in Tuberculosis (Prevention) in USA (Intradermal) (NCT02063555)
  • 01 Mar 2016 Phase II clinical trials in Tuberculosis (Prevention) in Tanzania (Intradermal) (NCT02712424)
  • 04 Nov 2015 Dartmouth Medical Centre, Muhimbili University of Health and Allied Sciences and Tokyo Medical and Dental University receives grant from the Global Health Innovative Technology Fund for DAR 901 development in Tuberculosis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top